REDX inhibitor provides multiple opportunities for cancer associated fibrosis

Published on 12 May 2023

Data from the companyâs lead fibrosis asset called RXC700 has highlighted multiple opportunities for patients with pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC).

Continue reading on website
Other news

Orgenesis secures $5M investment for point-of-care service subsidiary

12 May 2023
Orgenesis has secured $5 million from Metalmark Capital Partners to accelerate the growth of its point-of-care (POCare) services subsidiary.

Flexible Modernization: A Roadmap

12 May 2023
Digital technologies help plants achieve better data management while retaining legacy infrastructure. By Aaron Crews, Emerson Today’s operations teams face more challenges than ever before as management focuses on efficiency […]The post Flexible Modernization: A Roadmap appeared first on Efficient Plant.